BeStock  
Stocks › Biotechnology › PTGX

Protagonist Therapeutics PTGX

US equityMarket cap rank #1605Biotechnology
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–

Earnings

Average move on report day±19.7%last 5 reports
Closed higher2 of 540% of the time
Best reaction+83.7%
Worst reaction-6.2%

Stock move on the day after each report

-3.2%2017/Q4-1.5%2018/Q4-6.2%2019/Q4+83.7%2020/Q1+4.1%2020/Q4
QuarterReport dateTimingImplied moveActual moveVersus implied
2020/Q410 Mar 2021After Market±15.8%+4.09%Within range
2020/Q17 May 2020None–+83.70%–
2019/Q410 Mar 2020After Market–-6.16%–
2018/Q412 Mar 2019After Market–-1.46%–
2017/Q47 Mar 2018After Market–-3.16%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$274.41M+5,723.6% YoY
Operating profit$218.33M+570.3% YoY
Net profit$220.02M+659.3% YoY
Diluted EPS$3.07+595.2% YoY
Free cash flow-$23.46M-1,058.4% YoY
Operating cash flow-$23.22M

Revenue, last 8 quarters

$170.6MDec '24$28.3MMar '25$5.5MJun '25$4.7MSep '25$7.4MDec '25$56.4MMar '26$213.5MJun '26$274.4MSep '26

Net profit, last 8 quarters

$131.7MDec '24$-11.7MMar '25$-34.8MJun '25$-39.3MSep '25$-44.4MDec '25$3.8MMar '26$162.8MJun '26$220.0MSep '26

Profitability & balance sheet

Gross margin99.6%
Operating margin58.6%
Net margin62.0%
Return on equity39.6%
Return on assets37.0%
Return on invested capital36.1%
Current ratio19.85
Liabilities / assets5.4%
Cash & investments$800.06M
Total debt$6.18M
Net cash (debt)$793.89M
Free cash flow / sales19.8%

Discussion

No comments yet — be the first to weigh in on PTGX.

Sign in to join the discussion.

Scroll to Top